# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst David Nierengarten reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and maintains $23 price ta...
Cantor Fitzgerald analyst Li Watsek reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Overweight and maintains $20 price t...
Cantor Fitzgerald analyst Li Watsek initiates coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Overweight rating and ann...
Canaccord Genuity analyst Bill Maughan maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $26 price target.
Morgan Stanley analyst Michael Ulz maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Underweight and lowers the price targe...
HC Wainwright & Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $22 price...